CVS 헬스에 대한 분석은 최근 실적 성과와 헬스케어 혜택 부문의 구조적 변화라는 두 가지 핵심 축을 중심으로 이루어져야 합니다. 첫째, 실적 측면에서 회사는 모든 분기 보고서에서 매출 및 수익성 예상치를 상회했습니다. 이는 회사가 시장의 기대치를 뛰어넘는 운영 효율성과 수익 창출 능력을 입증하며, 이는 주가 상승의 강력한 근거가 됩니다. 예를 들어, 첫 분기 순이익(비일반회계기준)이 컨센서스보다 높게 나온 것은 회사의 내부 운영이 매우 효율적임을 보여줍니다. 둘째, 헬스케어 혜택 부문의 MBR(의료 혜택 비율) 추세는 매우 중요합니다. MBR은 보험료 대비 지출 비율을 나타내므로, 이 지표가 하락하는 추세는 보험료 관리 및 비용 통제에 있어 긍정적인 변화가 있음을 의미합니다. 기사에 제시된 MBR의 변동성(94.8%에서 84.6%로의 하락 및 87.4%로의 회복)은 보험 시장의 복잡한 역학 관계와 의료 서비스 비용의 변화가 CVS 헬스에 미치는 영향을 보여줍니다. 이러한 지표의 개선 추세는 회사가 보험료 수입을 효과적으로 관리하고 비용을 효율적으로 통제하고 있다는 점을 시사합니다.

다만, 이러한 긍정적인 분석에도 불구하고, 미래 전망은 외부 환경에 크게 의존합니다. 의료 서비스 비용의 지속적인 상승 압력과 보험 시장의 규제 환경 변화는 잠재적인 위험 요인으로 작용할 수 있습니다. 따라서 투자자들은 MBR의 추세뿐만 아니라, 의료 서비스 수요의 변화와 보험 규제 환경에 대한 거시적인 분석을 병행해야 합니다. 장기적인 성공은 이러한 외부 변수들을 얼마나 효과적으로 관리하고 혁신적인 헬스케어 서비스를 제공하는지에 달려 있다고 판단됩니다. 따라서 CVS 헬스의 주가는 현재의 실적과 지표 개선을 기반으로 하되, 미래의 거시 경제 및 규제 환경 변화에 대한 민감도를 함께 평가하는 것이 중요합니다. 이는 투자자들이 잠재적인 위험을 인지하고 합리적인 포트폴리오를 구축하는 데 도움을 줄 것입니다.

---

원문 링크: https://www.fool.com/investing/2026/08/22/cvs-health-stock-is-beating-the-market-in-2026/?.tsrc=rss

CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.

One of the hotter stocks in big healthcare just now is pharmacy chain mainstay CVS Health ( CVS -0.67% ) . The company's shares have raced more than 18% higher year to date, comparing favorably to the benchmark S&P 500 index's sub-13% rise.

And, according to most analysts tracking the stock, the stock's not done yet. According to data compiled by TipRanks, the consensus pundit price target is $114.59 per share, which is 22% above its most recent closing level.

Let's open the doors of this busy pharmacy to determine how it got here, and whether it can indeed continue to move higher.

Beating analysts' earning estimates

Any company that delivers two estimates-crushing quarters in a row is going to be a juicy buy candidate for investors. In all three of the quarterly earnings reports that CVS published this calendar year, it topped consensus analyst estimates for revenue and profitability. Investors are more impressed by the latter, naturally, so the company looked particularly good with its convincing beats in both the first and second frames.

First-quarter net income not under generally accepted accounting principles (non-GAAP, or adjusted) came in at $2.57 per share against the analyst consensus of $2.21. The gap for the following reporting period was much wider, at $2.58 and $1.83, respectively. Better -- since stocks trade on future potential instead of trailing performance -- CVS raised both its top- and bottom-line guidance in each of those two quarters.

What's going right for CVS? A major factor is its healthcare benefits segment, anchored by giant insurer Aetna, which saw a sharp drop in its medical benefit ratio (MBR) in the first quarter. The MBR is a key metric in the health insurance field, as it measures the percentage of collected premiums that are paid out for claims (so a lower figure is better for CVS).

The company's fourth quarter of 2025 MBR was 94.8%, then swooned to 84.6% before increasing modestly to 87.4% in the two subsequent periods. Keeping more premium money positively affected profitability: Adjusted operating income for healthcare benefits rose 52% year over year in the first quarter to over $3 billion, and 85% in the second quarter to $2.4 billion.

Big bunch of buy recommendations

In the analyst pen, the bulls are running wild for CVS. The TipRanks page on the company shows that 16 of the 17 prognosticators it tracks rate the stock a buy. One CVS optimist is UBS ' Kevin Caliendo, who raised his price target (to $126 per share from $122) and maintained a buy recommendation after that second-quarter report.

While he acknowledged that the company was facing challenges, including operational missteps at its CVS Caremark pharmacy benefits manager (PBM), he was bullish about the vast improvements in healthcare benefits. He also noted that, in his estimation, the prospects for CVS' pharmacy and consumer wellness segment -- its retail business -- are growing.

Though 22% might sound like an ambitious price-target growth forecast for the stock of a large, sprawling, and well-established company, CVS' insurance operations are going gangbusters, and the company is selling into an American population that's getting proportionally older (and therefore requiring more of what it sells). Personally, I think CVS stock could rise past that level.

Source: https://www.fool.com/investing/2026/08/22/cvs-health-stock-is-beating-the-market-in-2026/?.tsrc=rss